AI assistant
Sending…
Design Therapeutics, Inc. — Director's Dealing 2021
Aug 18, 2021
33059_dirs_2021-08-17_18fed8ea-48be-4973-b568-9c09b52a99a3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-08-13
Reporting Person: Giangiulio Dawn (Principal Accounting Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 7500 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $0.95 | 2030-04-08 | Common Stock (12269) | Direct | |
| Stock option (right to buy) | $0.95 | 2030-12-06 | Common stock (24539) | Direct |
Footnotes
F1: 25% of the shares vested on March 30, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F2: 25% of the shares shall vest on December 7, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.
More from Design Therapeutics, Inc.
Regulatory Filings
2026
May 18
Proxy Solicitation & Information Statement
2026
Apr 23
Annual Report
2026
Apr 23
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Feb 17
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5